Patients with type 2 diabetes who are treated by diet alone achieve significant reductions in haemoglobin A1c (HbA1c), postprandial glucose and insulin when treated with miglitol therapy.
A clinical trial conducted by M. L. Drent and colleagues at the VU Medical Center, in Amsterdam, The Netherlands, suggests that the optimal dose of the alpha-glucosidase inhibitor for most patients would be between 50 and 100 mg, three times a day.
The double-blind, placebo-controlled study, involved 468 patients with type 2 diabetes treated only by diet. Patients were randomly divided into a placebo group and four treatment groups receiving 25 mg, 50 mg, 100 mg, or 200 mg of miglitol three times a day.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!